Switch to:
More From Other Websites
Zacks.com featured highlights: Arcos Dorados Holdings, Corcept Therapeutics, Exelixis, Hecla Mining... Jun 29 2016
Explosive Stocks Under $10 Jun 28 2016
Biotech Stock Bounce Picks Up Momentum Jun 23 2016
'Mad Money' Lightning Round: I'm Sticking With Wells Fargo Jun 15 2016
Research Coverage Scans Stocks on the Biotechnology Industry for Today Jun 08 2016
Exelixis Up on Positive Kidney Cancer Data on Cabometyx Jun 07 2016
Exelixis (EXEL) Shows Strength: Stock Moves 11.2% Higher Jun 07 2016
Here’s Why These Five Stocks Are Surging Today Jun 06 2016
Exelixis (EXEL) Stock Gains on Positive Trial Results for Kidney Cancer Treatment Jun 06 2016
Exelixis and Its Partner Ipsen Announce Positive Overall Survival Results from Subgroup Analyses of... Jun 06 2016
Exelixis and its partner Ipsen announce positive overall survival results from subgroup analyses of... Jun 06 2016
Exelixis's stock surges after positive results from trial of kidney cancer treatment Jun 06 2016
Exelixis and Its Partner Ipsen Announce Positive Overall Survival Results from Subgroup Analyses of... Jun 06 2016
Exelixis Inc Investor/Analyst Briefing to Review Cabozantinib Data at the American Society of... Jun 05 2016
Exelixis and Its Partner Ipsen Announce Phase 3 Trial Results of CABOMETYX™ (Cabozantinib) Tablets... Jun 05 2016
Exelixis Announces Genentech Presentation of Preliminary Phase 1B Trial Results for the Combination... Jun 05 2016
Exelixis Announces Genentech Presentation of Preliminary Phase 1B Trial Results for the Combination... Jun 05 2016
EXELIXIS, INC. Files SEC form 8-K, Change in Directors or Principal Officers, Submission of Matters... May 26 2016
Exelixis' Kidney Cancer Drug Cabometyx Positive in Phase II May 24 2016
Ipsen’s partner Exelixis announced results from randomized phase 2 trial CABOSUN that demonstrate... May 23 2016
Exelixis Announces Results from Randomized Phase 2 Trial CABOSUN Demonstrate Cabozantinib... May 23 2016
Exelixis to Present at the Bank of America Merrill Lynch 2016 Health Care Conference on May 10 May 05 2016
Exelixis reports 1Q loss May 04 2016
Exelixis Announces First Quarter 2016 Financial Results and Provides Corporate Update May 04 2016
Exelixis Announces First Quarter 2016 Financial Results and Provides Corporate Update May 04 2016
Exelixis to Release First Quarter 2016 Financial Results on Wednesday, May 4, 2016 Apr 26 2016
Ipsen is pleased to announce that its partner Exelixis obtained FDA Approval of CABOMETYX™... Apr 26 2016
ADDING MULTIMEDIA Exelixis Announces FDA Approval of CABOMETYX™ (Cabozantinib) Tablets for... Apr 25 2016
Exelixis Announces FDA Approval of CABOMETYX™ (Cabozantinib) Tablets for Patients with Advanced... Apr 25 2016
Exelixis-Discovered Compounds to Be Featured in 18 Presentations at 2016 ASCO Annual Meeting Apr 20 2016
Exelixis reports 4Q loss Feb 29 2016
Exelixis and Ipsen Enter into Exclusive Licensing Agreement to Commercialize and Develop Novel... Feb 29 2016
Exelixis Announces Positive Overall Survival Results from METEOR, the Phase 3 Pivotal Trial of... Feb 01 2016
Exelixis Announces Positive Results From Subgroup Analyses of the METEOR Phase 3 Pivotal Trial of... Jan 04 2016
Exelixis Completes Submission of New Drug Application for Cabozantinib for the Treatment of Advanced... Dec 23 2015
Exelixis Announces European Commission Approval of COTELLIC™ (Cobimetinib) for Use in Combination... Nov 25 2015
Exelixis Announces Presentation of Positive Overall Survival Results for COTELLIC™ in Combination... Nov 21 2015
Exelixis reports 3Q loss Nov 10 2015
Exelixis reports 2Q loss Aug 11 2015
Exelixis reports 1Q loss Apr 30 2015
Exelixis reports 4Q loss Feb 24 2015
Ahead of the Bell: Exelixis shares climb, FDA to review drug Feb 19 2015
Exelixis tops 3Q profit forecasts Nov 04 2014
Ahead of the Bell: Exelixis shares soar Sep 29 2014
Ahead of the Bell: Exelixis shares tumble Sep 02 2014
Exelixis to cut jobs after prostate cancer drug fails late-stage study Sep 01 2014


Add Notes, Comments

If you want to ask a question or report a bug, please create a support ticket.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK